nach oben

Erschienen in:

01.08.2012

Rehmannia glutinosa Suppresses Inflammatory Responses Elicited by Advanced Glycation End Products

verfasst von: Gui-Hyun Baek, Yong-Suk Jang, Seung-Il Jeong, Jaeho Cha, Myungsoo Joo, Sang-Woo Shin, Ki-Tae Ha, Han-Sol Jeong

Erschienen in: Inflammation | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Fresh rhizome of Rehmannia glutinosa Libosch. (Saeng-jihwang in Korean: SJH) has been prescribed for the treatment of diabetes-associated complications. The purpose of the present study is to investigate the underlying mechanisms of the efficacy of SJH in diabetes-related complications. Decoction was obtained after boiling SJH in water and subsequent lyophilization. The cellular toxicity of SJH was determined by MTT assay. The antioxidant activity of SJH was measured by DPPH and DCFH-DA assays. The effects of SJH on inflammatory responses elicited by AGEs were assessed by western blotting and semi-quantitative RT-PCR analyses. The water extract of SJH had a high free radical scavenging activity in vitro and decreased the level of intracellular ROS in THP-1 cells treated with AGEs. SJH suppressed the expression of pro-inflammatory genes, including TNF-α, MCP-1, IP-10, COX-2, and iNOS; the activation of NF-κB; and the expression of RAGE, a receptor for AGEs, where the expressions of which were induced by AGEs. These results suggest the possibility that SJH can be an alternative therapeutics for diabetes-associated diseases.

Nur mit Berechtigung zugänglich

Ahmed, N. 2005. Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Research and Clinical Practice 67: 3–21.PubMedCrossRef

Bierhaus, A., M.A. Hofmann, R. Ziegler, and P.P. Nawroth. 1998. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovascular Research 37: 586–600.PubMedCrossRef

Singh, R., A. Barden, T. Mori, and L. Beilin. 2001. Advanced glycation end-products: a review. Diabetologia 44: 129–146.PubMedCrossRef

Turk, Z., S. Ljubic, N. Turk, and B. Benko. 2001. Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. Clinica chimica acta; international journal of clinical chemistry 303: 105–115.PubMedCrossRef

Yamamoto, Y., I. Kato, T. Doi, H. Yonekura, S. Ohashi, M. Takeuchi, et al. 2001. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. The Journal of Clinical Investigation 108: 261–268.PubMed

Harja, E., D.X. Bu, B.I. Hudson, J.S. Chang, X. Shen, K. Hallam, et al. 2008. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. The Journal of Clinical Investigation 118: 183–194.PubMedCrossRef

Forbes, J.M., L.T. Yee, V. Thallas, M. Lassila, R. Candido, K.A. Jandeleit-Dahm, et al. 2004. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53: 1813–1823.PubMedCrossRef

Wada, R., and S. Yagihashi. 2005. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Annals of the New York Academy of Sciences 1043: 598–604.PubMedCrossRef

Peyroux, J., and M. Sternberg. 2006. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathologie-Biologie 54: 405–419.PubMedCrossRef

10.

Fosmark, D.S., P.A. Torjesen, B.K. Kilhovd, T.J. Berg, L. Sandvik, K.F. Hanssen, et al. 2006. Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism, Clinical and Experimental 55: 232–236.CrossRef

11.

Huebschmann, A.G., J.G. Regensteiner, H. Vlassara, and J.E. Reusch. 2006. Diabetes and advanced glycoxidation end products. Diabetes Care 29: 1420–1432.PubMedCrossRef

12.

Desai, K., and L. Wu. 2007. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons? Recent Patents on Cardiovascular Drug Discovery 2: 89–99.PubMedCrossRef

13.

Edelstein, D., and M. Brownlee. 1992. Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41: 26–29.PubMedCrossRef

14.

Nakamura, S., Z. Makita, S. Ishikawa, K. Yasumura, W. Fujii, K. Yanagisawa, et al. 1997. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46: 895–899.PubMedCrossRef

15.

Doggrell, S.A. 2001. ALT-711 decreases cardiovascular stiffness and has potential in diabetes, hypertension and heart failure. Expert Opinion on Investigational Drugs 10: 981–983.PubMedCrossRef

16.

Oturai, P.S., M. Christensen, B. Rolin, K.E. Pedersen, S.B. Mortensen, and E. Boel. 2000. Effects of advanced glycation end-product inhibition and cross-link breakage in diabetic rats. Metabolism, Clinical and Experimental 49: 996–1000.CrossRef

17.

Stitt, A., T.A. Gardiner, N.L. Alderson, P. Canning, N. Frizzell, N. Duffy, et al. 2002. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826–2832.PubMedCrossRef

18.

Figarola, J.L., S. Scott, S. Loera, C. Tessler, P. Chu, L. Weiss, et al. 2003. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46: 1140–1152.PubMedCrossRef

19.

Huang, W.J., H.S. Niu, M.H. Lin, J.T. Cheng, and F.L. Hsu. 2010. Antihyperglycemic effect of catalpol in streptozotocin-induced diabetic rats. Journal of Natural Products 73: 1170–1172.PubMedCrossRef

20.

Kubo, M., T. Asano, H. Shiomoto, and H. Matsuda. 1994. Studies on rehmanniae radix. I. Effect of 50% ethanolic extract from steamed and dried rehmanniae radix on hemorheology in arthritic and thrombosic rats. Biological and Pharmaceutical Bulletin 17: 1282–1286.PubMedCrossRef

21.

Kiho, T., T. Watanabe, K. Nagai, and S. Ukai. 1992. Hypoglycemic activity of polysaccharide fraction from rhizome of Rehmannia glutinosa Libosch. f. hueichingensis Hsiao and the effect on carbohydrate metabolism in normal mouse liver. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan 112: 393–400.PubMed

22.

Yokozawa, T., H.Y. Kim, and N. Yamabe. 2004. Amelioration of diabetic nephropathy by dried rehmanniae radix (Di Huang) extract. The American Journal of Chinese Medicine 32: 829–839.PubMedCrossRef

23.

Kang, D.G., E.J. Sohn, M.K. Moon, Y.M. Lee, and H.S. Lee. 2005. Rehmannia glutinose ameliorates renal function in the ischemia/reperfusion-induced acute renal failure rats. Biological and Pharmaceutical Bulletin 28: 1662–1667.PubMedCrossRef

24.

Kim, H.M., C.S. An, K.Y. Jung, Y.K. Choo, J.K. Park, and S.Y. Nam. 1999. Rehmannia glutinosa inhibits tumour necrosis factor-alpha and interleukin-1 secretion from mouse astrocytes. Pharmacological research: the official journal of the Italian Pharmacological Society 40: 171–176.CrossRef

25.

Ashoor, S.H., and J.B. Zent. 1984. Maillard browning of common amino-acids and sugars. Journal of Food Science 49: 1206–1207.CrossRef

26.

Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65: 55–63.PubMedCrossRef

27.

Brandwilliams, W., M.E. Cuvelier, and C. Berset. 1995. Use of a free-radical method to evaluate antioxidant activity. Food Sci Technol-Lebensm-Wiss Technol 28: 25–30.

28.

Ramasamy, R., S.J. Vannucci, S.S. Yan, K. Herold, S.F. Yan, and A.M. Schmidt. 2005. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15: 16R–28R.PubMedCrossRef

29.

Baeuerle, P.A., and D. Baltimore. 1996. NF-kappa B: ten years after. Cell 87: 13–20.PubMedCrossRef

30.

Barnes, P.J., and M. Karin. 1997. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. The New England Journal of Medicine 336: 1066–1071.PubMedCrossRef

31.

May, M.J., and S. Ghosh. 1997. Rel/NF-kappa B and I kappa B proteins: an overview. Seminars in Cancer Biology 8: 63–73.PubMedCrossRef

32.

Collins, T. 1993. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Laboratory investigation; a journal of technical methods and pathology 68: 499–508.PubMed

33.

Read, M.A., M.Z. Whitley, A.J. Williams, and T. Collins. 1994. NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. The Journal of Experimental Medicine 179: 503–512.PubMedCrossRef

34.

Verma, I.M., J.K. Stevenson, E.M. Schwarz, D. Van Antwerp, and S. Miyamoto. 1995. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes & Development 9: 2723–2735.CrossRef

35.

Pouliot, M., J. Baillargeon, J.C. Lee, L.G. Cleland, and M.J. James. 1997. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. Journal of Immunology 158: 4930–4937.

36.

Zhang, G., and S. Ghosh. 2001. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. The Journal of Clinical Investigation 107: 13–19.PubMedCrossRef

37.

Lander, H.M., J.S. Ogiste, R.A. Moss, D. Stern, and A.M. Schmidt. 1995. Advanced glycation endproducts (ages) induce activation of nuclear factor-kappaB (NF-kB) by a signaling mechanism involving p21(ras) and map kinase via the receptor for ages (rage). Circulation 92: 532–532.

38.

Schmidt, A.M., O. Hori, R. Cao, S.D. Yan, J. Brett, J.L. Wautier, et al. 1996. RAGE—a novel cellular receptor for advanced glycation end products. Diabetes 45: S77–S80.PubMedCrossRef

39.

Sousa, M.M., S. Du Yan, D. Stern, and M.J. Saraiva. 2000. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Laboratory Investigation 80: 1101–1110.PubMedCrossRef

40.

Vlassara, H., and M.R. Palace. 2002. Diabetes and advanced glycation endproducts. Journal of Internal Medicine 251: 87–101.PubMedCrossRef

41.

Brownlee, M. 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615–1625.PubMedCrossRef

42.

Yan, S.D., A.M. Schmidt, G.M. Anderson, J.H. Zhang, J. Brett, Y.S. Zou, et al. 1994. Enhanced cellular oxidant stress by the interaction of advanced glycation end-products with their receptors binding-proteins. Journal of Biological Chemistry 269: 9889–9897.PubMed

43.

Lander, H.M., J.M. Tauras, J.S. Ogiste, O. Hori, R.A. Moss, and A.M. Schmidt. 1997. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. Journal of Biological Chemistry 272: 17810–17814.PubMedCrossRef

44.

Stern, D., S.D. Yan, S.F. Yan, and A.M. Schmidt. 2002. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Advanced Drug Delivery Reviews 54: 1615–1625.PubMedCrossRef

45.

Yamagishi, S.I., K. Nakamura, T. Matsui, S. Ueda, K. Fukami, and S. Okuda. 2008. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opinion on Investigational Drugs 17: 983–996.PubMedCrossRef

46.

Jiang, Y., D.I. Beller, G. Frendl, and D.T. Graves. 1992. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. Journal of Immunology 148: 2423–2428.

47.

Wakabayashi, Y., Y. Usui, Y. Okunuki, T. Kezuka, M. Takeuchi, H. Goto, et al. 2010. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina 30: 339–344.PubMedCrossRef

48.

Miura, T., M. Kako, E. Ishihara, M. Usami, H. Yano, K. Tanigawa, et al. 1997. Antidiabetic effect of seishin-kanro-to in KK-Ay mice. Planta Medica 63: 320–322.PubMedCrossRef

49.

Meng, Q.Y., X.F. Lv, and X.D. Jin. 2008. [Effect of Rehmannia glutinosa Libosch water extraction on gene expression of proinsulin in type 2 diabetes mellitus rats]. Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials 31: 397–399.PubMed

50.

Waisundara, V.Y., M. Huang, A. Hsu, D. Huang, and B.K. Tan. 2008. Characterization of the anti-diabetic and antioxidant effects of Rehmannia glutinosa in streptozotocin-induced diabetic Wistar rats. The American Journal of Chinese Medicine 36: 1083–1104.PubMedCrossRef

51.

Lee, H.S., S.T. Kim, and D.K. Cho. 1993. Effects of rehmanniae radix water extract on renal function and renin secretion rate in unanesthetized rabbits. The American Journal of Chinese Medicine 21: 179–186.PubMedCrossRef

52.

Li, S.L., J.Z. Song, C.F. Qiao, Y. Zhou, K. Qian, K.H. Lee, et al. 2010. A novel strategy to rapidly explore potential chemical markers for the discrimination between raw and processed radix rehmanniae by UHPLC-TOFMS with multivariate statistical analysis. Journal of Pharmaceutical and Biomedical Analysis 51: 812–823.PubMedCrossRef

53.

Huang, W.J., F.S. Niu, M.H. Lin, J.T. Cheng, and F.L. Hsu. 2010. Antihyperglycemic effect of catalpol in streptozotocin-induced diabetic rats. Journal of Natural Products 73: 1170–1172.PubMedCrossRef

54.

Wang, C.F., D.Q. Li, H.Y. Xue, and B. Hu. 2010. Oral supplementation of catalpol ameliorates diabetic encephalopathy in rats. Brain Research 1307: 158–165.PubMedCrossRef

55.

Shieh, J.P., K.C. Cheng, H.H. Chung, Y.F. Kerh, C.H. Yeh, and J.T. Cheng. 2011. Plasma glucose lowering mechanisms of catalpol, an active principle from roots of Rehmannia glutinosa, in streptozotocin-induced diabetic rats. Journal of Agricultural and Food Chemistry 59: 3747–3753.PubMedCrossRef

56.

Tian, Y.Y., L.J. An, L. Jiang, Y.L. Duan, J. Chen, and B. Jiang. 2006. Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures. Life Sciences 80: 193–199.PubMedCrossRef

57.

Bi, J., B. Jiang, J.H. Liu, C. Lei, X.L. Zhang, and L.J. An. 2008. Protective effects of catalpol against H₂O₂-induced oxidative stress in astrocytes primary cultures. Neuroscience Letters 442: 224–227.PubMedCrossRef

Titel: Rehmannia glutinosa Suppresses Inflammatory Responses Elicited by Advanced Glycation End Products
verfasst von: Gui-Hyun Baek
Yong-Suk Jang
Seung-Il Jeong
Jaeho Cha
Myungsoo Joo
Sang-Woo Shin
Ki-Tae Ha
Han-Sol Jeong
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 4/2012
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-012-9433-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Rehmannia glutinosa Suppresses Inflammatory Responses Elicited by Advanced Glycation End Products

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

A Novel Combination of Methotrexate and Epigallocatechin Attenuates the Overexpression of Pro-inflammatory Cartilage Cytokines and Modulates Antioxidant Status in Adjuvant Arthritic Rats

HSF1 Is a Transcriptional Activator of IL-10 Gene Expression in RAW264.7 Macrophages

The Efficiency of Proanthocyanidin in an Experimental Pulmonary Fibrosis Model: Comparison with Taurine

Bacterial Cell Wall Constituents Induce Hepcidin Expression in Macrophages Through MyD88 Signaling

Pioglitazone, PPARγ Agonist, Attenuates Experimental Autoimmune Neuritis

Oxidized LDLs Inhibit TLR-induced IL-10 Production by Monocytes: A New Aspect of Pathogen-Accelerated Atherosclerosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin